The Molecular Cytogenetics Core provides valuable scientific and technical support to MSK investigators exploring the role of chromosomal instability in cancer. This is accomplished through appropriate and efficient experiment design, custom multi-color DNA-FISH probe design and development, data analysis and interpretation, and support with manuscript/grant preparation. Currently, the Core provides 2 main categories of specialized service that operate at the single-cell level on a variety of human and animal model research samples: conventional karyotyping and fluorescence in situ hybridization (FISH). Conventional karyotyping is routinely performed to confirm cell line identity, screen targeted mouse ESC clones intended for blastocyst injection, monitor the stability of cultured stem cells over time, and measure chromosomal instability/heterogeneity as an experimental endpoint. Over the years, the Core has assembled a broad range of molecular cytogenetics resources (plasmids, BAC clones, individual whole chromosome painting probes), allowing the Core to provide FISH services at significantly lower cost. FISH-based assays are routinely employed to map genes or transgene integration sites, detect aneuploidy/chromosomal instability, co-detect DNA/protein and assess intra-tumoral heterogeneity; tests include custom probe development, locus-specific FISH, whole-chromosome painting (WCP), spectral karyotyping (SKY), Q-FISH, and Immuno-FISH. The Core is equipped with 5 modern Fluorescence imaging systems including 2 with a wide range of applications that can be fully or partially automated. The Core also provides training in tissue culture, karyotyping, and FISH. During the past grant period, the services and collaborative work provided by the Molecular Cytogenetics Core have supported the research of 84 investigators from 8 research program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084813
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Buckley, Benjamin J; Aboelela, Ashraf; Minaei, Elahe et al. (2018) 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer. J Med Chem 61:8299-8320
Geller, Shamir; Canavan, Theresa N; Pulitzer, Melissa et al. (2018) ALK-positive primary cutaneous anaplastic large cell lymphoma: a case report and review of the literature. Int J Dermatol 57:515-520
Assel, Melissa; Dahlin, Anders; Ulmert, David et al. (2018) Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 73:961-967
Pak, Linda M; Gonen, Mithat; Seier, Kenneth et al. (2018) Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma? Abdom Radiol (NY) 43:2113-2118
McHugh, Deaglan J; Root, James C; Nelson, Christian J et al. (2018) Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire? Cancer 124:1326-1334
Shoag, Jonathan; Liu, Deli; Blattner, Mirjam et al. (2018) SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. J Clin Invest 128:381-386
Assel, Melissa J; Gerdtsson, Axel; Thorek, Daniel L J et al. (2018) Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmö preventive project. Oncotarget 9:5778-5785
Katsoulakis, Evangelia; Leeman, Jonathan E; Lok, Benjamin H et al. (2018) Long-term outcomes in oral cavity squamous cell carcinoma with adjuvant and salvage radiotherapy after surgery. Laryngoscope 128:2539-2545
Breitbart, William (2018) In Memoriam: Jimmie C. Holland, MD, 1928-2017. Palliat Support Care 16:124-126
Hoseini, Sayed Shahabuddin; Guo, Hongfen; Wu, Zhihao et al. (2018) A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. Blood Adv 2:1250-1258

Showing the most recent 10 out of 8799 publications